26
views
0
recommends
+1 Recommend
2 collections
    1
    shares

      Submit your digital health research with an established publisher
      - celebrating 25 years of open access

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      SARS-CoV-2 Omicron Variant Genomic Sequences and Their Epidemiological Correlates Regarding the End of the Pandemic: In Silico Analysis

      research-article
      , MD 1 , 2 , , , MD 1 , 2 , , PhD 2 , 3 , , PhD 2 , 4 , , PhD 2 , 5 , , MD 2 , 6 , , MBBS 1 , 2 , , MBBS 1 , 2 , , MD 2 , 7 , , MD 1 , 2 , , MD 2 , 8 , , PhD 2 , 9 , , MD 2 , 10 , , MD 2 , 11 , , PhD 2 , 12
      (Reviewer), (Reviewer)
      Jmir Bioinformatics and Biotechnology
      JMIR Publications
      COVID-19, pandemic, variants, immune escape, transmissibility, virulence, policy, mutations, epidemiology, data, Omicron, virus, transmission, genomic

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Emergence of the new SARS-CoV-2 variant B.1.1.529 worried health policy makers worldwide due to a large number of mutations in its genomic sequence, especially in the spike protein region. The World Health Organization (WHO) designated this variant as a global variant of concern (VOC), which was named “Omicron.” Following Omicron’s emergence, a surge of new COVID-19 cases was reported globally, primarily in South Africa.

          Objective

          The aim of this study was to understand whether Omicron had an epidemiological advantage over existing variants.

          Methods

          We performed an in silico analysis of the complete genomic sequences of Omicron available on the Global Initiative on Sharing Avian Influenza Data (GISAID) database to analyze the functional impact of the mutations present in this variant on virus-host interactions in terms of viral transmissibility, virulence/lethality, and immune escape. In addition, we performed a correlation analysis of the relative proportion of the genomic sequences of specific SARS-CoV-2 variants (in the period from October 1 to November 29, 2021) with matched epidemiological data (new COVID-19 cases and deaths) from South Africa.

          Results

          Compared with the current list of global VOCs/variants of interest (VOIs), as per the WHO, Omicron bears more sequence variation, specifically in the spike protein and host receptor-binding motif (RBM). Omicron showed the closest nucleotide and protein sequence homology with the Alpha variant for the complete sequence and the RBM. The mutations were found to be primarily condensed in the spike region (n=28-48) of the virus. Further mutational analysis showed enrichment for the mutations decreasing binding affinity to angiotensin-converting enzyme 2 receptor and receptor-binding domain protein expression, and for increasing the propensity of immune escape. An inverse correlation of Omicron with the Delta variant was noted (r=–0.99, P<.001; 95% CI –0.99 to –0.97) in the sequences reported from South Africa postemergence of the new variant, subsequently showing a decrease. There was a steep rise in new COVID-19 cases in parallel with the increase in the proportion of Omicron isolates since the report of the first case (74%-100%). By contrast, the incidence of new deaths did not increase (r=–0.04, P>.05; 95% CI –0.52 to 0.58).

          Conclusions

          In silico analysis of viral genomic sequences suggests that the Omicron variant has more remarkable immune-escape ability than existing VOCs/VOIs, including Delta, but reduced virulence/lethality than other reported variants. The higher power for immune escape for Omicron was a likely reason for the resurgence in COVID-19 cases and its rapid rise as the globally dominant strain. Being more infectious but less lethal than the existing variants, Omicron could have plausibly led to widespread unnoticed new, repeated, and vaccine breakthrough infections, raising the population-level immunity barrier against the emergence of new lethal variants. The Omicron variant could have thus paved the way for the end of the pandemic.

          Related collections

          Most cited references69

          • Record: found
          • Abstract: found
          • Article: not found

          Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus

          Summary A SARS-CoV-2 variant carrying the Spike protein amino acid change D614G has become the most prevalent form in the global pandemic. Dynamic tracking of variant frequencies revealed a recurrent pattern of G614 increase at multiple geographic levels: national, regional and municipal. The shift occurred even in local epidemics where the original D614 form was well established prior to the introduction of the G614 variant. The consistency of this pattern was highly statistically significant, suggesting that the G614 variant may have a fitness advantage. We found that the G614 variant grows to higher titer as pseudotyped virions. In infected individuals G614 is associated with lower RT-PCR cycle thresholds, suggestive of higher upper respiratory tract viral loads, although not with increased disease severity. These findings illuminate changes important for a mechanistic understanding of the virus, and support continuing surveillance of Spike mutations to aid in the development of immunological interventions.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

            The COVID-19 pandemic has had widespread effects across the globe, and its causative agent, SARS-CoV-2, continues to spread. Effective interventions need to be developed to end this pandemic. Single and combination therapies with monoclonal antibodies have received emergency use authorization1-3, and more treatments are under development4-7. Furthermore, multiple vaccine constructs have shown promise8, including two that have an approximately 95% protective efficacy against COVID-199,10. However, these interventions were directed against the initial SARS-CoV-2 virus that emerged in 2019. The recent detection of SARS-CoV-2 variants B.1.1.7 in the UK11 and B.1.351 in South Africa12 is of concern because of their purported ease of transmission and extensive mutations in the spike protein. Here we show that B.1.1.7 is refractory to neutralization by most monoclonal antibodies against the N-terminal domain of the spike protein and is relatively resistant to a few monoclonal antibodies against the receptor-binding domain. It is not more resistant to plasma from individuals who have recovered from COVID-19 or sera from individuals who have been vaccinated against SARS-CoV-2. The B.1.351 variant is not only refractory to neutralization by most monoclonal antibodies against the N-terminal domain but also by multiple individual monoclonal antibodies against the receptor-binding motif of the receptor-binding domain, which is mostly due to a mutation causing an E484K substitution. Moreover, compared to wild-type SARS-CoV-2, B.1.351 is markedly more resistant to neutralization by convalescent plasma (9.4-fold) and sera from individuals who have been vaccinated (10.3-12.4-fold). B.1.351 and emergent variants13,14 with similar mutations in the spike protein present new challenges for monoclonal antibody therapies and threaten the protective efficacy of current vaccines.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding

              Summary The receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein mediates viral attachment to ACE2 receptor, and is a major determinant of host range and a dominant target of neutralizing antibodies. Here we experimentally measure how all amino-acid mutations to the RBD affect expression of folded protein and its affinity for ACE2. Most mutations are deleterious for RBD expression and ACE2 binding, and we identify constrained regions on the RBD’s surface that may be desirable targets for vaccines and antibody-based therapeutics. But a substantial number of mutations are well tolerated or even enhance ACE2 binding, including at ACE2 interface residues that vary across SARS-related coronaviruses. However, we find no evidence that these ACE2-affinity enhancing mutations have been selected in current SARS-CoV-2 pandemic isolates. We present an interactive visualization and open analysis pipeline to facilitate use of our dataset for vaccine design and functional annotation of mutations observed during viral surveillance.
                Bookmark

                Author and article information

                Contributors
                Journal
                JMIR Bioinform Biotech
                JMIR Bioinform Biotech
                JBB
                Jmir Bioinformatics and Biotechnology
                JMIR Publications (Toronto, Canada )
                2563-3570
                2023
                10 January 2023
                10 January 2023
                : 4
                : e42700
                Affiliations
                [1 ] Department of Anatomy All India Institute of Medical Sciences-Patna Patna India
                [2 ] Etiologically Elusive Disorders Research Network New Delhi India
                [3 ] Department of Systems Biology Columbia University Irving Medical Center New York, NY United States
                [4 ] New York University Langone Health Center Robert I Grossman School of Medicine New York University New York, NY United States
                [5 ] Center for Proteomics and Drug Discovery Amity Institute of Biotechnology Amity University, Maharashtra Mumbai India
                [6 ] Dr BC Roy Multi-speciality Medical Research Centre Indian Institute of Technology Kharagpur India
                [7 ] Department of Anatomy Institute of Medical Sciences Banaras Hindu University Varanasi India
                [8 ] Department of Biochemistry Maulana Azad Medical College New Delhi India
                [9 ] School of Medicine University of Pittsburgh Pittsburgh, PA United States
                [10 ] Department of Anatomy All India Institute of Medical Sciences-Mangalagiri Mangalagiri India
                [11 ] Department of Microbiology All India Institute of Medical Sciences-Bathinda Bathinda India
                [12 ] Department of Zoology Banaras Hindu University Varanasi India
                Author notes
                Corresponding Author: Ashutosh Kumar drashutoshkumar@ 123456aiimspatna.org
                Author information
                https://orcid.org/0000-0003-1589-9568
                https://orcid.org/0000-0002-1404-1298
                https://orcid.org/0000-0003-4111-5165
                https://orcid.org/0000-0002-1430-3139
                https://orcid.org/0000-0001-5427-8735
                https://orcid.org/0000-0003-2510-6744
                https://orcid.org/0000-0002-3100-8908
                https://orcid.org/0000-0001-8756-1676
                https://orcid.org/0000-0002-4301-4643
                https://orcid.org/0000-0003-1292-5927
                https://orcid.org/0000-0002-6769-2596
                https://orcid.org/0000-0002-5035-3619
                https://orcid.org/0000-0002-6196-5565
                https://orcid.org/0000-0002-8966-6268
                https://orcid.org/0000-0003-3201-2287
                Article
                v4i1e42700
                10.2196/42700
                9843602
                36688013
                bc081706-9771-4451-bb65-672a36a5ec6d
                ©Ashutosh Kumar, Adil Asghar, Himanshu N Singh, Muneeb A Faiq, Sujeet Kumar, Ravi K Narayan, Gopichand Kumar, Prakhar Dwivedi, Chetan Sahni, Rakesh K Jha, Maheswari Kulandhasamy, Pranav Prasoon, Kishore Sesham, Kamla Kant, Sada N Pandey. Originally published in JMIR Bioinformatics and Biotechnology (https://bioinform.jmir.org), 10.01.2023.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Bioinformatics and Biotechnology, is properly cited. The complete bibliographic information, a link to the original publication on https://bioinform.jmir.org/, as well as this copyright and license information must be included.

                History
                : 15 September 2022
                : 11 November 2022
                : 29 November 2022
                : 16 December 2022
                Categories
                Original Paper
                Original Paper

                covid-19,pandemic,variants,immune escape,transmissibility,virulence,policy,mutations,epidemiology,data,omicron,virus,transmission,genomic

                Comments

                Comment on this article